only with
Healthcare
Small-cap - With a market cap of ₹216.47 Cr.
| EX-Date | Purpose |
|---|---|
| 25 05 2021 | Audited Results |
| 09 08 2021 | Quarterly Results & Interim Dividend |
| 09 11 2021 | Quarterly Results |
| 08 02 2022 | Quarterly Results |
| 26 05 2022 | Final Dividend & Audited Results |
| 08 08 2022 | Quarterly Results |
| 11 11 2022 | Quarterly Results |
| 10 02 2023 | Quarterly Results |
| 30 05 2023 | Dividend & Audited Results |
| 14 08 2023 | Quarterly Results |
| 09 11 2023 | Quarterly Results |
| 08 02 2024 | Quarterly Results |
| 13 11 2024 | Quarterly Results |
| 11 02 2025 | Quarterly Results |
| 30 05 2025 | Dividend & Audited Results |
News
AstraZeneca Pharma receives CDSCO’s permission for Tremelimumab Concentrate
Through this approval, Tremelimumab (Imjudo) in combination with Durvalumab (Imfinzi) is indicated for the treatment of patients with unresectable hepatocellular carcinoma
AstraZeneca Pharma India gets nod to import pharmaceutical formulations of new drug
The company has received approval from Central Drugs Standard Control Organisation
AstraZeneca Pharma India gets CDSCO’s nod to import, distribute Durvalumab solutions
Durvalumab in combination with Tremelimumab is indicated for the treatment of patients with unresectable hepatocellular carcinoma
AstraZeneca Pharma gets permission to Import for sale and distribution of Trastuzumab deruxtecan solution
Trastuzumab deruxtecan is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen
AstraZeneca Pharma gets nod to import Osimertinib Tablets 40 mg & 80 mg
The receipt of this permission paves way for the marketing of Osimertinib Tablets 40 mg & 80 mg in India for the specified additional indication
AstraZeneca Pharma India gets nod to import, distribute Sodium Zirconium Cyclosilicate powder
Through this approval, Sodium Zirconium Cyclosilicate is indicated for the treatment of hyperkalaemia in adult patients
AstraZeneca Pharma India to launch Eculizumab (Soliris)
Eculizumab (Soliris) is indicated for the treatment of patients with PNH and aHUS to inhibit complement
AstraZeneca Pharma India launches Selumetinib capsule in India
Earlier, the company had received Import and Market Permission in Form CT-20 from the Drugs Controller General of India for Selumetinib (Koselugo)
AstraZeneca Pharma India, Mankind Pharma enter into agreement
AstraZeneca will retain the intellectual property rights to budesonide and formoterol fumarate dihydrate and will continue to be the Marketing Authorisation Holder and import license
AstraZeneca Pharma surrenders marketing authorisation of prostate cancer treatment drug in India
The company had received marketing authorisation for Olaparib film-coated tablets 100mg and 150mg (Lynparza) on November 17, 2023
AstraZeneca Pharma India gets nod to market Durvalumab Solution
The company has received permission from the Central Drugs Standard Control Organisation, Directorate General of Health Services, Government of India
AstraZeneca Pharma India planning to exit manufacturing site in Bangalore
The Company will position the manufacturing site for sale in a fully operational manner
AstraZeneca Pharma to launch Breztri Aerosphere in January 2025
In December 2023, the company had received import and market permission in Form CT-20 from the Drugs Controller General of India for Breztri Aerosphere
AstraZeneca Pharma gets nod to import pharmaceutical formulations of new drug for sale
The company has received permission from Central Drugs Standard Control Organisation
AstraZeneca Pharma to launch Trastuzumab deruxtecan in January 2024
Enhertu is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen
AstraZeneca Pharma gets permission to import pharmaceutical formulations
The receipt of this permission paves way for the launch of Olaparib film coated tablets of 100mg/150mg (Lynparza) in India
AstraZeneca Pharma gets nod to import Durvalumab solution
The receipt of this permission paves way for the launch of Durvalumab 120 mg/2.4 mL and 500 mg/10 mL solution for infusion (Imfinzi) in India for the specified additional indication
AstraZeneca Pharma receives permission from DCGI for Dapagliflozin Tablets
Through this approval, Dapagliflozin Tablets 10mg is indicated for the treatment of heart failure in adults
AstraZeneca Pharma gets nod to import for sale, distribution of Trastuzumab deruxtecan lyophilized powder
The company has received permission from the Central Drugs Standard Control Organisation
AstraZeneca Pharma gets import, market permission for Forxiga tablets
The receipt of this permission paves way for the launch of Forxiga tablets of 10 mg in India for the specified additional/expanded indication
Astrazeneca Pharma India receives approval to import for sale and distribution of Osimertinib Tablets
The company has received permission from the CDSCO to import for sale and distribution of Osimertinib Tablets 40 mg & 80 mg (TAGRISSO) for an additional indication
AstraZeneca Pharma gets permission to import for sale and distribution of Benralizumab
Benralizumab is indicated as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis
